Market closed
Edgewise Therapeutics/$EWTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Edgewise Therapeutics
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
Ticker
$EWTX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
108
Website
EWTX Metrics
BasicAdvanced
$2.9B
Market cap
-
P/E ratio
-$1.46
EPS
0.15
Beta
-
Dividend rate
Price and volume
Market cap
$2.9B
Beta
0.15
52-week high
$35.66
52-week low
$8.64
Average daily volume
811K
Financial strength
Current ratio
26.346
Quick ratio
25.982
Long term debt to equity
0.705
Total debt to equity
0.908
Management effectiveness
Return on assets (TTM)
-22.36%
Return on equity (TTM)
-31.90%
Valuation
Price to book
5.94
Price to tangible book (TTM)
5.94
Price to free cash flow (TTM)
-23.742
Growth
Earnings per share change (TTM)
3.69%
3-year earnings per share growth (CAGR)
0.66%
What the Analysts think about EWTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Edgewise Therapeutics stock.
EWTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
EWTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
EWTX News
AllArticlesVideos
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
Benzinga·6 days ago
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
Business Wire·6 days ago
Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Edgewise Therapeutics stock?
Edgewise Therapeutics (EWTX) has a market cap of $2.9B as of December 22, 2024.
What is the P/E ratio for Edgewise Therapeutics stock?
The price to earnings (P/E) ratio for Edgewise Therapeutics (EWTX) stock is 0 as of December 22, 2024.
Does Edgewise Therapeutics stock pay dividends?
No, Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Edgewise Therapeutics dividend payment date?
Edgewise Therapeutics (EWTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Edgewise Therapeutics?
Edgewise Therapeutics (EWTX) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.